Healthcare Industry News: Defibtech
News Release - May 1, 2006
MediQuest Save-a-Life Program to Distribute 1,500 Defibtech AEDsVANCOUVER, British Columbia--May 1, 2006 (HSMN NewsFeed)--Concurrent with today's launch of North American Occupational Safety and Health Week, British Columbia company MediQuest Technologies Inc. and Defibtech LLC jointly announced plans to distribute over the next year 1,500 MediQuest AED Save-a-Life Programs including the Defibtech Lifeline AED(R) (automated external defibrillator) to Canadian retail locations, workplaces and public facilities.
MediQuest President Chris Metcalfe said the AED deployment, which is scheduled to begin at the end of May, will be Canada's largest single distribution of AEDs to date. In addition to distributing the Defibtech AEDs, the MediQuest AED Save-a-Life Program will provide medical direction and training to all participating locations. Metcalfe also is the Canadian chairman of the launch committee of North American Occupational Safety and Health Week, which is celebrated during the first week of May in Canada, Mexico, and the United States.
Kevin Vinding, 44, was revived by an AED after suffering a series of cardiac arrests while playing hockey in Saskatoon. "I know that I'm the luckiest man alive today," Vinding said. "I owe my life to the defibrillator and all the individuals that were there to help me. I was given a second chance a lot of people don't get." An AED also saved Detroit Red Wings defenseman Jiri Fischer after he suffered sudden cardiac arrest during a game earlier this hockey season.
The AED training will be given in English or French to as many as 15,000 individuals across Canada, Metcalfe estimated. The Defibtech AED's voice prompts - which "talk" to the user, providing audible instructions on lifesaving defibrillation, will be available in English or French, as well. Metcalfe said an anonymous donor provided the funding for the deployment in response to several studies showing that AEDs in public facilities and workplaces save lives.
Defibtech AEDs have been deployed in many locations around the world - in thousands of police, fire and emergency vehicles in the United States, at the 2006 Winter Olympic Games in Torino, Italy, and at countless other public facilities and workplaces. "Defibtech's Lifeline AED(R) and ReviveR(TM) have become the defibrillators of choice for large-scale deployments," said Gintaras Vaisnys, Defibtech's president. Defibtech AEDs make a wise choice because of their reliability, durability and reasonable price, he said.
AEDs revive victims of sudden cardiac arrest caused by ventricular fibrillation. Studies show that if victims are defibrillated within a minute or two after arrest, more than 70 percent survive. If defibrillation is delayed for more than 10 minutes, only 5 percent live, making immediate access to AEDs vital.
About MediQuest Technologies Inc.
MediQuest Technologies Inc. is a coast-to-coast Canadian provider of MediQuest AED Save-a-Life Programs - a turnkey safety and health solution that includes Defibtech AEDs, medical direction, training and related services. For more information about MediQuest, visit www.mediquest.ca or call 1-866-831-3227.
Defibtech relentlessly pursues one goal: making the best automated external defibrillators (AEDs) in the world at affordable prices. Defibtech designs and manufactures the FDA-approved Lifeline(R) and ReviveR(TM) brand AEDs and related accessories including pediatric defibrillation pads. Defibtech's products and services, including DefibtechMD, are sold through its network of distribution partners in the United States and around the world. Founded in 1999, Defibtech is headquartered in Guilford, Conn., and manufactures all of its defibrillators in the United States in a state-of-the-art ISO-9001 certified facility. The company also has CE Marking approval and ISO 13485 certification. For more information about Defibtech and its products, visit www.Defibtech.com or call 1-866-DEFIB-4-U (1-866-333-4248).
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.